Maze Therapeutics IncMaze Therapeutics Inc
Maze Therapeutics Inc

Maze Therapeutics Inc

MAZE
Health Care·Biotechnology

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

California; U.S.A
Market cap
No dataNo data
Revenue
$167.5M0.0% YoY
Net income
$-131.1M−351.0% YoY
Free cash flow
$-112.7M−250.7% YoY

Market

Listed stock
MAZEPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$167.5M0.0% YoY
Operating income
$-142.9M−348.1% YoY
Net income
$-131.1M−351.0% YoY
Free cash flow
$-112.7M−250.7% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2022 $0, 2023 $0, 2024 $167.5M, 2025 $167.5M. Operating income: 2022 $-111M, 2023 $-98.6M, 2024 $57.6M, 2025 $-142.9M. Net income: 2022 $-114.9M, 2023 $-100.4M, 2024 $52.2M, 2025 $-131.1M. Free cash flow: 2022 $-101.2M, 2023 $-87.3M, 2024 $74.8M, 2025 $-112.7M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
0.0%No data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2022-12-31 $-111M, 2023-12-31 $-98.6M, 2024-12-31 $57.6M, 2025-12-31 $-142.9M. Net income: 2022-12-31 $-114.9M, 2023-12-31 $-100.4M, 2024-12-31 $52.2M, 2025-12-31 $-131.1M. Free cash flow: 2022-12-31 $-101.2M, 2023-12-31 $-87.3M, 2024-12-31 $74.8M, 2025-12-31 $-112.7M

Growth heatmap

202320242025CAGR
Revenue
No data
No data
0.0%
No data
Gross profit
No data
No data
-103.8%
No data
Operating income
+11.2%
+158.4%
-348.1%
No data
Free cash flow
+13.7%
+185.7%
-250.7%
No data

Earnings quality

Operating cash flow
$-111.9M−247.4% YoY
Net income
$-131.1M−351.0% YoY
Free cash flow
$-112.7M−250.7% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 85%, 2024-12-31 145%, 2023-12-31 86%, 2022-12-31 86%. Free cash flow: 2025-12-31 86%, 2024-12-31 143%, 2023-12-31 87%, 2022-12-31 88%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data